FDA Staff Raises Concerns on Breast, Prostate Cancer Drug Applications

FDA staff have raised concerns about the benefit-risk profiles of two cancer drug applications targeting breast and prostate cancer, ahead of the first Oncologic Drugs Advisory Committee (ODAC) meeting since July of last year. The advisory committee is set to convene on Thursday to evaluate both applications, despite positive clinical trial results cited by the drug sponsors. The FDA's reservations suggest that the agency sees potential issues with the magnitude of clinical benefit or the safety profile of the treatments under review. ODAC recommendations, while non-binding, carry significant weight and often influence final FDA approval decisions. The outcome of this meeting could have important implications for treatment options available to patients with these two common cancer types.